SCHEMBL4696875

SCHEMBL4696875

COCc1ccc(OC)c(Br)c1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.54
SMN1; SMN2 Q16637 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
HTT P42858 1/20 0.51
ALDH1A1 P00352 5/20 0.49
KDM4E B2RXH2 2/20 0.49
GAA P10253 1/20 0.49
TDP1 Q9NUW8 1/20 0.48
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
DBH P09172 1/20 0.48
GFER P55789 1/20 0.46
MAPK1 P28482 1/20 0.46
APOBEC3G Q9HC16 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
CA2 P00918 1/20 0.45
OPRK1 P41145 1/20 0.45
POLB P06746 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30526544 1.00 MAPT (0.54) MAPTSMN1; SMN2L3MBTL1HTTALDH1A1
SCHEMBL12293826 0.85 HTT (0.53) MAPTSMN1; SMN2L3MBTL1HTTALDH1A1
SCHEMBL31063263 0.82 MAPT (0.49) MAPTSMN1; SMN2L3MBTL1HTTALDH1A1
SCHEMBL333582 0.82 MAPT (0.56) MAPTSMN1; SMN2L3MBTL1HTTALDH1A1
SCHEMBL29463290 0.82 MAPT (0.56) MAPTSMN1; SMN2L3MBTL1HTTALDH1A1
SCHEMBL580639 0.82 MAPT (0.56) MAPTSMN1; SMN2L3MBTL1HTTALDH1A1
SCHEMBL2500053 0.82 MAPT (0.56) MAPTSMN1; SMN2L3MBTL1HTTALDH1A1
SCHEMBL291363 0.81 CA2 (0.68) MAPTALDH1A1KDM4EGAAKMT2A
SCHEMBL4799519 0.81 PTPN1 (0.41) MAPTSMN1; SMN2L3MBTL1HTTCA2
SCHEMBL12765969 0.80 MAPT (0.48) MAPTSMN1; SMN2L3MBTL1HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026766-A1 Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors BEIGENE, LTD. (KY) 2025-01-23 US disclosed
US-20240277683-A1 COMPOUNDS CTXT PTY LTD (AU) 2024-08-22 US disclosed
US-11911372-B2 Compounds CTXT PTY LTD (AU) 2024-02-27 US disclosed
US-11911372-B2 Compounds CTXT PTY LTD (AU) 2024-02-27 US disclosed
CN-117069724-A Fused ring compounds, pharmaceutical compositions and uses 上海赛默罗德生物科技有限公司 2023-11-17 CN disclosed
US-20210213004-A1 Compounds CTXT PTY LTD (AU) 2021-07-15 US disclosed
EP-3813813-A1 COMPOUNDS CTXT Pty Limited (AU) 2021-05-05 EP disclosed
EP-1463501-B1 CIS-IMIDAZOLINES AS MDM2 INHIBITORS HOFFMANN LA ROCHE (CH) 2008-06-11 EP disclosed
US-6617346-B1 Inhibit the interaction of MDM2 protein with a p53-like peptide and have antiproliferative activity HOFFMANN-LA ROCHE INC. 2003-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240277683-A1 COMPOUNDS SLC10A1, ABCB11, REN MAPT 1141/4885SMN1; SMN2 998/4885L3MBTL1 4767/4885
US-20250026766-A1 Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors POLQ, POLK, POLI MAPT 544/4885SMN1; SMN2 4018/4885L3MBTL1 2693/4885
US-20210213004-A1 Compounds SLC10A1, ABCB11, REN MAPT 1236/4885SMN1; SMN2 1164/4885L3MBTL1 4762/4885
US-11911372-B2 Compounds SLC10A1, ABCB11, REN MAPT 1236/4885SMN1; SMN2 1164/4885L3MBTL1 4762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.